Two reports have shown that increasing levels of miR-34a and miR-23a tumor suppressors by metformin treatment require a concomitant induction of p53 in breast cancer and hepatocellular carcinoma cells, respectively [53,54]. The gene discussed is TP53; the disease is breast carcinoma.